Longevity Technology: 'Hufford interview: "It’s worth pointing out just how remarkable this is."'

LyGenesis CEO Michael Hufford, PhD , speaks with Longevity Technology during the Longevity 2020 conference, as a part of the Advisory Board, about longevity research, programs and investments. Dr. Hufford discusses the progress of their studies and trials at LyGenesis, its transition from a preclinical to clinical biotech company and what’s next.

Dr. Hufford shares LyGenesis’ approach to drug development success, his investor recommendations and what is most compelling to investors about organ growth related to the longevity sector.

Read the full article at Longevity Technology.